Investigational Drug Information for ONC201
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for ONC201?
ONC201 is an investigational drug.
There have been 27 clinical trials for ONC201.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2022.
The most common disease conditions in clinical trials are Glioma, Glioblastoma, and Endometrial Neoplasms. The leading clinical trial sponsors are Oncoceutics, Inc., Chimerix, and National Cancer Institute (NCI).
There are fourteen US patents protecting this investigational drug and one hundred and seventy-eight international patents.
Summary for ONC201
| US Patents | 14 |
| International Patents | 178 |
| US Patent Applications | 53 |
| WIPO Patent Applications | 9 |
| Japanese Patent Applications | 7 |
| Clinical Trial Progress | Phase 2 (2022-09-01) |
| Vendors | 50 |
Recent Clinical Trials for ONC201
| Title | Sponsor | Phase |
|---|---|---|
| Testing ONC201 to Prevent Colorectal Cancer | National Cancer Institute (NCI) | Phase 1 |
| ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) | Chimerix | Phase 3 |
| ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer | Genentech, Inc. | Phase 1 |
Clinical Trial Summary for ONC201
Top disease conditions for ONC201
Top clinical trial sponsors for ONC201
US Patents for ONC201
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ONC201 | See Plans and Pricing | 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]- pyrimidin-5 (1h)-one, salts thereof and methods of using the same in combination therapy | Oncoceutics, Inc. (Philadelphia, PA) | See Plans and Pricing |
| ONC201 | See Plans and Pricing | Imipridones for gliomas | Oncoceutics, Inc. (Philadelphia, PA) | See Plans and Pricing |
| ONC201 | See Plans and Pricing | 7-Benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-A]pyrido[3,4-E]pyrimidin-5(1H)-one, analogs thereof, and salts thereof and methods for their use in therapy | Oncoceutics, Inc. (Philadelphia, PA) | See Plans and Pricing |
| ONC201 | See Plans and Pricing | Imipridones for gliomas | Oncoceutics, Inc. (Philadelphia, PA) | See Plans and Pricing |
| ONC201 | See Plans and Pricing | 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]- pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy | Oncoceutics, Inc. (Philadelphia, PA) | See Plans and Pricing |
| ONC201 | See Plans and Pricing | Methods of cancer treatment | K-Gen, Inc. (Burlingame, CA) | See Plans and Pricing |
| ONC201 | See Plans and Pricing | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy | The Penn State Research Foundation (University Park, PA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ONC201
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ONC201 | Australia | AU2014244117 | 2033-03-13 | See Plans and Pricing |
| ONC201 | Australia | AU2014349150 | 2033-03-13 | See Plans and Pricing |
| ONC201 | Australia | AU2019201896 | 2033-03-13 | See Plans and Pricing |
| ONC201 | Australia | AU2020200875 | 2033-03-13 | See Plans and Pricing |
| ONC201 | Australia | AU2020233606 | 2033-03-13 | See Plans and Pricing |
| ONC201 | Australia | AU2022203043 | 2033-03-13 | See Plans and Pricing |
| ONC201 | Brazil | BR112015023256 | 2033-03-13 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
